funding through cash, staff and other resources to sell, market, promote and further develop these products.

Recent Product Launches

We continue to invest in clinical research for our in-line medicines, increasing the value of our medicines to patients and their healthcare providers. We are also reinvigorating our portfolio by launching a series of new medicines or existing medicines in new markets. The following highlights the achievements for several of these products in 2005:

• Macugen, for treatment of AMD, the leading cause of blindness in people over 60, was launched in the U.S. in January 2005 and approved in the E.U. in 2006. While new competitors are expected to enter the market, Macugen has a strong foothold with more than 40,000 patients treated to date. Macugen’s favorable safety profile has been maintained for more than two years of clinical testing and marketing.

• Revatio, for treatment of pulmonary arterial hypertension (PAH) was approved by the FDA in June 2005 and by the EMEA in November 2005.

• Zmax, for treatment of mild-to-moderate acute bacterial sinusitis and community acquired pneumonia in adult patients appropriate for oral therapy due to susceptible pathogens was launched in the U.S. in August 2005.

• Lyrica, for add-on therapy for adult epilepsy patients with partial onset seizures, as well as neuropathic pain due to diabetic neuropathy and post-herpetic neuralgia, was launched in the U.S. in September 2005 with more than 500,000 prescriptions written as of December 23, 2005. Lyrica has already gained more than a 7% new-prescription share of the U.S. anti-epileptic market as of December 23, 2005.

Consumer Healthcare

Revenues of our Consumer Healthcare business follow:

Our Consumer Healthcare business is one of the largest in the world.

On February 7, 2006, we announced that we are exploring strategic options for our Consumer Healthcare business, including a possible sale or spin-off of the business.

The increase in Consumer Healthcare revenues in 2005, as compared to 2004, was attributable to:

• the 11% increase in 2005 in sales of Listerine mouthwash, which benefited from the U.S. launch of Listerine Whitening in April 2005, as well as continued strong performance in international markets;

• the 13% growth from upper-respiratory products, 55% growth from Zantac, and 15% growth from tobacco dependence products;

• inclusion of Purell sales in 2005 following the acquisition of the Purell brand in November 2004; and

• the favorable impact of the weakening of the U.S. dollar relative to many foreign currencies.

The increase in Consumer Healthcare revenues in 2004, as compared to 2003, was attributable to:

• the 22% increase in 2004 in sales of Listerine mouthwash, which benefited from the U.S. launch of Natural Citrus flavor in September 2003 and the launch of Listerine Advanced in September 2004;

• the favorable impact of the weakening of the U.S. dollar relative to many foreign currencies; and

• the inclusion of Pharmacia product revenues for a full year in 2004.

 Animal Health

Our Animal Health business is one of the largest in the world.

The increase in Animal Health revenues in 2005, as